Heidi Barth - Search Results

Year	Number of Results
2002	2
2003	2
2004	1
2005	2
2006	3
2007	4
2008	4
2009	3
2010	3
2011	2
2012	2
2014	3
2015	5
2016	3
2017	5
2018	2
2024	0

1

In Vitro and In Vivo Models for the Study of Human Polyomavirus Infection.

Barth H, Solis M, Kack-Kack W, Soulier E, Velay A, Fafi-Kremer S. Barth H, et al. Viruses. 2016 Oct 22;8(10):292. doi: 10.3390/v8100292. Viruses. 2016. PMID: 27782080 Free PMC article. Review.

2

Development of hepatitis C virus vaccines: challenges and progress.

Stoll-Keller F, Barth H, Fafi-Kremer S, Zeisel MB, Baumert TF. Stoll-Keller F, et al. Among authors: barth h. Expert Rev Vaccines. 2009 Mar;8(3):333-45. doi: 10.1586/14760584.8.3.333. Expert Rev Vaccines. 2009. PMID: 19249975 Free PMC article. Review.

3

Persistent infectious diseases say - IDO. Role of indoleamine-2,3-dioxygenase in disease pathogenesis and implications for therapy.

Barth H, Raghuraman S. Barth H, et al. Crit Rev Microbiol. 2014 Nov;40(4):360-8. doi: 10.3109/1040841X.2012.742037. Epub 2012 Nov 23. Crit Rev Microbiol. 2014. PMID: 23174025 Review.

4

Hepatitis C virus entry: molecular biology and clinical implications.

Barth H, Liang TJ, Baumert TF. Barth H, et al. Hepatology. 2006 Sep;44(3):527-35. doi: 10.1002/hep.21321. Hepatology. 2006. PMID: 16941688 Review.

5

Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy.

Zeisel MB, Barth H, Schuster C, Baumert TF. Zeisel MB, et al. Among authors: barth h. Front Biosci (Landmark Ed). 2009 Jan 1;14(9):3274-85. doi: 10.2741/3450. Front Biosci (Landmark Ed). 2009. PMID: 19273272 Free PMC article. Review.

6

45 years after the discovery of human polyomaviruses BK and JC: Time to speed up the understanding of associated diseases and treatment approaches.

Barth H, Solis M, Lepiller Q, Sueur C, Soulier E, Caillard S, Stoll-Keller F, Fafi-Kremer S. Barth H, et al. Crit Rev Microbiol. 2017 Mar;43(2):178-195. doi: 10.1080/1040841X.2016.1189873. Epub 2016 Nov 1. Crit Rev Microbiol. 2017. PMID: 27800693 Review.

7

Challenges for HCV vaccine development in HIV-HCV coinfection.

Lambotin M, Barth H, Moog C, Habersetzer F, Baumert TF, Stoll-Keller F, Fafi-Kremer S. Lambotin M, et al. Among authors: barth h. Expert Rev Vaccines. 2012 Jul;11(7):791-804. doi: 10.1586/erv.12.52. Expert Rev Vaccines. 2012. PMID: 22913257 Review.

8

Neutralizing antibodies in hepatitis C virus infection.

Zeisel MB, Fafi-Kremer S, Fofana I, Barth H, Stoll-Keller F, Doffoel M, Baumert TF. Zeisel MB, et al. Among authors: barth h. World J Gastroenterol. 2007 Sep 28;13(36):4824-30. doi: 10.3748/wjg.v13.i36.4824. World J Gastroenterol. 2007. PMID: 17828813 Free PMC article. Review.

9

Insights into the role of interferon lambda in hepatitis C virus infection.

Barth H. Barth H. J Hepatol. 2011 May;54(5):844-7. doi: 10.1016/j.jhep.2010.10.008. Epub 2010 Oct 25. J Hepatol. 2011. PMID: 21145814 Free article. No abstract available.

10

A look behind closed doors: interaction of persistent viruses with dendritic cells.

Lambotin M, Raghuraman S, Stoll-Keller F, Baumert TF, Barth H. Lambotin M, et al. Among authors: barth h. Nat Rev Microbiol. 2010 May;8(5):350-60. doi: 10.1038/nrmicro2332. Epub 2010 Apr 7. Nat Rev Microbiol. 2010. PMID: 20372157 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

39 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

39 results

Results by year